Cargando…

Does Pathologic Response Equate to Clinical Response Following SABR for Early-Stage NSCLC?

Detalles Bibliográficos
Autores principales:	Brooks, Eric D., Verma, Vivek, Chang, Joe Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598426/ https://www.ncbi.nlm.nih.gov/pubmed/31293978 http://dx.doi.org/10.3389/fonc.2019.00551

Ejemplares similares

Scalpel or SABR for Treatment of Early-Stage Lung Cancer: Clinical Considerations for the Multidisciplinary Team
por: Shirvani, Shervin M., et al.
Publicado: (2011)

Is MRI-Linac helpful in SABR treatments for liver cancer?
por: Tallet, Agnès, et al.
Publicado: (2023)

Radial Data Mining to Identify Density–Dose Interactions That Predict Distant Failure Following SABR
por: Davey, Angela, et al.
Publicado: (2022)

SABR-BRIDGE: Stereotactic ABlative Radiotherapy Before Resection to AvoId Delay for Early-Stage LunG Cancer or OligomEts During the COVID-19 Pandemic
por: Kidane, Biniam, et al.
Publicado: (2020)

Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study
por: Schneider, Marc A., et al.
Publicado: (2022)

Brief report: risk stratification following curative therapy for stage I NSCLC
por: Butts, Emily, et al.
Publicado: (2023)

Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer
por: Mercier, Carole, et al.
Publicado: (2022)

On the reduction of aperture complexity in kidney SABR
por: Gaudreault, Mathieu, et al.
Publicado: (2021)

DCE-MRI assessment of response to neoadjuvant SABR in early stage breast cancer: Comparisons of single versus three fraction schemes and two different imaging time delays post-SABR
por: Mouawad, Matthew, et al.
Publicado: (2019)

Complete pathological response of NSCLC
por: Kovács, K, et al.
Publicado: (2013)

Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1
por: Castello, Angelo, et al.
Publicado: (2020)

Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World
por: Pasello, Giulia, et al.
Publicado: (2022)

Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses
por: Zhang, Wei, et al.
Publicado: (2021)

Comprehensive dosimetric planning comparison for early‐stage, non‐small cell lung cancer with SABR: fixed‐beam IMRT versus VMAT versus TomoTherapy
por: Xhaferllari, Ilma, et al.
Publicado: (2016)

Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR)
por: Dhaliwal, Inderdeep, et al.
Publicado: (2022)

Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients
por: Grenda, Anna, et al.
Publicado: (2021)

Collaborative Care in NSCLC; the Role of Early Palliative Care
por: Howe, Marnie, et al.
Publicado: (2014)

Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
por: Evans, Rachel, et al.
Publicado: (2022)

Persistent Response and Prolonged Survival Following Pembrolizumab Discontinuation Due to Long-Lasting Autoimmune Colitis in Advanced NSCLC: A Case Report
por: Damato, Angela, et al.
Publicado: (2021)

Independent review of 4DCT scans used for SABR treatment planning
por: Antony, Rachitha, et al.
Publicado: (2020)

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
por: Lieverse, Relinde I. Y., et al.
Publicado: (2020)

Quantification of hyperpolarisation efficiency in SABRE and SABRE-Relay enhanced NMR spectroscopy
por: Richardson, Peter M., et al.
Publicado: (2018)

Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer
por: Goldman, Jonathan W., et al.
Publicado: (2023)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
por: Cekay, Michael, et al.
Publicado: (2023)

Analysis of predictive factors of unforeseen nodal metastases in resected clinical stage I NSCLC
por: Gallina, Filippo Tommaso, et al.
Publicado: (2023)

Early monocyte response following local ablation in hepatocellular carcinoma
por: Kimm, Melanie A., et al.
Publicado: (2022)

Dosimetric effects of immobilization devices on SABR for lung cancer using VMAT technique
por: Park, Jong In, et al.
Publicado: (2015)

Quantification of interplay and gradient effects for lung stereotactic ablative radiotherapy (SABR) treatments
por: Tyler, Madelaine K.
Publicado: (2016)

hνSABR: Photochemical Dose–Response Bead Screening in Droplets
por: Price, Alexander K., et al.
Publicado: (2016)

Obesity may not be related to pathologic response in locally advanced rectal cancer following neoadjuvant chemoradiotherapy
por: Bao, Quoc Riccardo, et al.
Publicado: (2022)

Development of a multi-feature-combined model: proof-of-concept with application to local failure prediction of post-SBRT or surgery early-stage NSCLC patients
por: Yang, Zhenyu, et al.
Publicado: (2023)

Stratification of Patients With Stage IB NSCLC Based on the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging Manual
por: Wu, Lei-Lei, et al.
Publicado: (2020)

The impact of staging FDG-PET/CT on treatment for stage III NSCLC - an analysis of population-based data from Ontario, Canada
por: Beers, Craig A., et al.
Publicado: (2023)

Development and validation of machine learning models to predict survival of patients with resected stage-III NSCLC
por: Jin, Long, et al.
Publicado: (2023)

Case report: an initially unresectable stage III pulmonary sarcomatoid carcinoma qith EGFR mutation achieving pathological complete response following neoadjuvant therapy with osimertinib plus chemotherapy
por: Liu, Xiguang, et al.
Publicado: (2022)

Optimization of the dosimetric leaf gap for use in planning VMAT treatments of spine SABR cases
por: Middlebrook, Nigel D, et al.
Publicado: (2017)

The case for SABR as the global standard for non-operable early-stage non-small cell lung cancer
por: Mutsaers, Adam, et al.
Publicado: (2022)

SABRE : sistema de reservaciones para agencias de viajes
por: Mata Hernández, Elizabeth
Publicado: (1999)

Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC)
por: Palma, David A., et al.
Publicado: (2017)

Exploring pathological signatures for predicting the recurrence of early-stage hepatocellular carcinoma based on deep learning
por: Qu, Wei-Feng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q90mh73ggefbnke4pkmciftmsr